MannKind Corporation (MNKD)
MNKD Stock Price Chart
Explore MannKind Corporation interactive price chart. Choose custom timeframes to analyze MNKD price movements and trends.
MNKD Company Profile
Discover essential business fundamentals and corporate details for MannKind Corporation (MNKD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Jul 2004
Employees
403.00
Website
https://www.mannkindcorp.comCEO
Michael E. Castagna
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Financial Timeline
Browse a chronological timeline of MannKind Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $0.01, while revenue estimate is $83.55M.
Earnings released on 6 Aug 2025
EPS came in at $0.00 falling short of the estimated $0.04 by -94.65%, while revenue for the quarter reached $76.53M , missing expectations by -4.53%.
Earnings released on 8 May 2025
EPS came in at $0.04 surpassing the estimated $0.03 by +33.33%, while revenue for the quarter reached $78.35M , missing expectations by -0.11%.
Earnings released on 26 Feb 2025
EPS came in at $0.03 matching the estimated $0.03, while revenue for the quarter reached $76.78M , beating expectations by +2.40%.
Earnings released on 7 Nov 2024
EPS came in at $0.04 falling short of the estimated $0.06 by -33.33%, while revenue for the quarter reached $70.08M , missing expectations by -6.40%.
Earnings released on 7 Aug 2024
EPS came in at $0.05 surpassing the estimated -$0.03 by +249.93%, while revenue for the quarter reached $72.39M , beating expectations by +11.69%.
Earnings released on 8 May 2024
EPS came in at $0.04 surpassing the estimated $0.03 by +53.85%, while revenue for the quarter reached $66.26M , beating expectations by +9.54%.
Earnings released on 27 Feb 2024
EPS came in at $0.02 , while revenue for the quarter reached $58.47M , beating expectations by +9.13%.
Earnings released on 7 Nov 2023
EPS came in at $0.02 surpassing the estimated $0.01 by +160.76%, while revenue for the quarter reached $51.25M , beating expectations by +1.05%.
Earnings released on 7 Aug 2023
EPS came in at -$0.02 falling short of the estimated -$0.01 by -47.38%, while revenue for the quarter reached $48.61M , beating expectations by +13.18%.
Earnings released on 9 May 2023
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%, while revenue for the quarter reached $40.63M , beating expectations by +8.63%.
Earnings released on 23 Feb 2023
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%, while revenue for the quarter reached $36.06M , beating expectations by +1.57%.
Earnings released on 8 Nov 2022
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $32.83M , beating expectations by +28.80%.
Earnings released on 9 Aug 2022
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $18.89M , beating expectations by +20.93%.
Earnings released on 5 May 2022
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $11.99M , beating expectations by +13.33%.
Earnings released on 24 Feb 2022
EPS came in at -$0.11 falling short of the estimated -$0.06 by -83.33%, while revenue for the quarter reached $12.52M , missing expectations by -26.70%.
Earnings released on 9 Nov 2021
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%, while revenue for the quarter reached $22.21M , beating expectations by +7.72%.
Earnings released on 11 Aug 2021
EPS came in at -$0.05 falling short of the estimated -$0.04 by -25.00%, while revenue for the quarter reached $23.28M , beating expectations by +33.10%.
Earnings released on 12 May 2021
EPS came in at -$0.05 falling short of the estimated -$0.04 by -17.65%, while revenue for the quarter reached $17.44M , beating expectations by +33.33%.
Earnings released on 25 Feb 2021
EPS came in at -$0.06 falling short of the estimated -$0.04 by -66.67%, while revenue for the quarter reached $18.44M , beating expectations by +21.21%.
Earnings released on 4 Nov 2020
EPS came in at -$0.05 falling short of the estimated -$0.05 by -8.70%, while revenue for the quarter reached $15.35M , meeting expectations.
MNKD Stock Performance
Access detailed MNKD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.